Home

Leeds kreativ Ökologie class action teva Seltenheit Schluchzen zwanzig

Teva settles shareholder lawsuit over generic drug | Business Insurance
Teva settles shareholder lawsuit over generic drug | Business Insurance

US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The  Times of Israel
US states sue Teva for price-fixing in 'multi-billion dollar fraud' | The Times of Israel

Teva Settles Price-Fixing-Related Securities Class Action Litigation for  $420 Million | The D&O Diary
Teva Settles Price-Fixing-Related Securities Class Action Litigation for $420 Million | The D&O Diary

Teva Pharmaceuticals Retirement Savings Plan $2.55M Class Action Settlement  - Top Class Actions
Teva Pharmaceuticals Retirement Savings Plan $2.55M Class Action Settlement - Top Class Actions

Teva Settles Price-Fixing-Related Securities Class Action Litigation for  $420 Million | The D&O Diary
Teva Settles Price-Fixing-Related Securities Class Action Litigation for $420 Million | The D&O Diary

Irbesartan, Losartan and Valsartan (Azido Impurity) Class Action - Rice  Harbut Elliott
Irbesartan, Losartan and Valsartan (Azido Impurity) Class Action - Rice Harbut Elliott

Teva charged in US price-fixing investigation | Financial Times
Teva charged in US price-fixing investigation | Financial Times

TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL:  KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000  of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva

Teva ponies up $420M to settle with investors who said company hid  price-fixing scheme | Fierce Pharma
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma

Trouble at Teva: US price-fixing lawsuit adds to generic giant's woes -  Pharma Technology Focus | Issue 85 | August 2019
Trouble at Teva: US price-fixing lawsuit adds to generic giant's woes - Pharma Technology Focus | Issue 85 | August 2019

Teva Shareholder Notice
Teva Shareholder Notice

Rosen Law Firm Files Securities Class Action Lawsuit Against Teva  Pharmaceutical Industries Limited - TEVA
Rosen Law Firm Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA

Teva Settles Price-Fixing-Related Securities Class Action Litigation for  $420 Million | The D&O Diary
Teva Settles Price-Fixing-Related Securities Class Action Litigation for $420 Million | The D&O Diary

If you bought Provigilo directly from Cephalon, you could get a
If you bought Provigilo directly from Cephalon, you could get a

Teva enters opioid settlement agreement with US state Rhode Island
Teva enters opioid settlement agreement with US state Rhode Island

Teva settles investor lawsuit for $420m - Globes
Teva settles investor lawsuit for $420m - Globes

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT ONTARIO TEACHERS'  PENSION PLAN BOARD, Individually and as Lead Plaintiff
UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT ONTARIO TEACHERS' PENSION PLAN BOARD, Individually and as Lead Plaintiff

Teva settles shareholder lawsuit over generic drug pricing for $420 mln |  Reuters
Teva settles shareholder lawsuit over generic drug pricing for $420 mln | Reuters

Teva Class Action Claims Company Suppressed Competition For Generic Version  Of MS Drug Copaxone - Top Class Actions
Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions

Is 2019 The Trough For Teva, Or Will 2020 Continue To See Pressure? (NYSE: TEVA) | Seeking Alpha
Is 2019 The Trough For Teva, Or Will 2020 Continue To See Pressure? (NYSE: TEVA) | Seeking Alpha

Teva settles investor lawsuit for $420m - Globes
Teva settles investor lawsuit for $420m - Globes

Pfizer and Teva face new drug delay action - Global Competition Review
Pfizer and Teva face new drug delay action - Global Competition Review

J&J, Teva and Other Opioid Drugmakers Face $50 Billion Lawsuit in  California | BioSpace
J&J, Teva and Other Opioid Drugmakers Face $50 Billion Lawsuit in California | BioSpace

US states accuse Teva and other drugmakers of colluding to inflate prices  over 1,000%
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%

Does Teva's $15M, 18-year opioid settlement with Louisiana signal the start  of a trend? | Fierce Pharma
Does Teva's $15M, 18-year opioid settlement with Louisiana signal the start of a trend? | Fierce Pharma

Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
Teva Pays $420 Million to End Generic-Drug Securities Suit (1)